Ph3 study assessing ziftomenib in combo with KMT2A Acute Myeloid
Phase III Clinical Trial
Phase 3 Randomized Double-blind Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax + Azacitidine) or Intensive (7+3) Therapy in Patients Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia (NCT05735184)
Participating Locations